Actio Biosciences is a research center that develops drugs for rare diseases.
Actio Biosciences has raised $66.0M in total funding. The most recent round was Series B. The last funding was announced in June 2025.
Actio Biosciences's investors include Deerfield Management, Canaan Partners, EcoR1 Capital, Droia Ventures, Regeneron Ventures.
Actio Biosciences is headquartered in San Diego, United States.
Actio Biosciences is a research center that develops drugs for rare diseases.
Actio Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Actio Biosciences — Funding & Investors." VCBacked, June 18, 2025, https://www.vcbacked.co/company/actio-biosciences. Accessed August 2, 2026.
VCBacked. (2025). Actio Biosciences — Funding & Investors. Retrieved August 2, 2026, from https://www.vcbacked.co/company/actio-biosciences
{{cite web |title=Actio Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/actio-biosciences |website=VCBacked |access-date=August 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated